scholarly journals Validation of the Grace Risk Score to Predict In-Hospital and 6-Month Post-Discharge Mortality in Patients with Acute Coronary Syndrome

Author(s):  
Vítor Boniatti Neves ◽  
Raquel Melchior Roman ◽  
Tiago Vendruscolo ◽  
Gilberto Heineck ◽  
Carlos Alberto Santos de Mattos ◽  
...  
Angiology ◽  
2012 ◽  
Vol 64 (1) ◽  
pp. 31-39 ◽  
Author(s):  
Sergio Raposeiras-Roubín ◽  
Pablo Aguiar-Souto ◽  
Cristina Barreiro-Pardal ◽  
Diego López Otero ◽  
Juliana Elices Teja ◽  
...  

2015 ◽  
Vol 4 (3) ◽  
pp. 216-221
Author(s):  
Adem Bekler ◽  
Gökhan Erbağ ◽  
Hacer Şen ◽  
Muhammed Turgut, Alper Özkan ◽  
Ali Ümit Yener ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (9) ◽  
pp. e032165 ◽  
Author(s):  
Colin C Everett ◽  
Keith AA Fox ◽  
Catherine Reynolds ◽  
Catherine Fernandez ◽  
Linda Sharples ◽  
...  

IntroductionFor non-ST-segment elevation acute coronary syndrome (NSTEACS) there is a gap between the use of class I guideline recommended therapies and clinical practice. The Global Registry of Acute Coronary Events (GRACE) risk score is recommended in international guidelines for the risk stratification of NSTEACS, but its impact on adherence to guideline-indicated treatments and reducing adverse clinical outcomes is unknown. The objective of the UK GRACE Risk Score Intervention Study (UKGRIS) trial is to assess the effectiveness of the GRACE risk score tool and associated treatment recommendations on the use of guideline-indicated care and clinical outcomes.Methods and analysisThe UKGRIS, a parallel-group cluster randomised registry-based controlled trial, will allocate hospitals in a 1:1 ratio to manage NSTEACS by standard care or according to the GRACE risk score and associated international guidelines. UKGRIS will recruit a minimum of 3000 patients from at least 30 English National Health Service hospitals and collect healthcare data from national electronic health records. The co-primary endpoints are the use of guideline-indicated therapies, and the composite of cardiovascular death, non-fatal myocardial infarction, new onset heart failure hospitalisation or cardiovascular readmission at 12 months. Secondary endpoints include duration of inpatient hospital stay over 12 months, EQ-5D-5L responses and utilities, unscheduled revascularisation and the components of the composite endpoint over 12 months follow-up.Ethics and disseminationThe study has ethical approval (North East - Tyne & Wear South Research Ethics Committee reference: 14/NE/1180). Findings will be announced at relevant conferences and published in peer-reviewed journals in line with the funder’s open access policy.Trial registration numberISRCTN29731761; Pre-results.


Sign in / Sign up

Export Citation Format

Share Document